tbuckley/cabot-search huggingface dataset:
Abstract IA12: Investigating the functional consequences of ATRX deficiency in glioma
Authors: Jason T. Huse
Journal: Cancer Research (2015)

Abstract Comprehensive genomic profiling in cancer continues to reveal frequent alterations in epigenetic regulators, firmly implicating chromatin biology in the oncogenic process. We and others recently found that inactivating mutations in the SWI/SNF family member ATRX represent defining molecular alterations in diffusely infiltrating gliomas, where they invariably pair with mutations in TP53 and IDH1/2. ATRX normally regulates the composition of histone monomers at a variety of sites across the genome, and may also affect the distribution of specific histone modifying complexes. A number of studies have linked ATRX deficiency to a wide spectrum of physiological dysfunction, including aberrant gene regulation, abnormal telomere maintenance, genomic instability, and aneuploidy. Nevertheless, the precise mechanisms by which ATRX deficiency promotes oncogenesis remain unknown. To investigate the effects of ATRX deficiency on chromatin structure, gene expression, and transformation, we inactivated Atrx in murine neuroepithelial progenitor cells (NPCs) also lacking Tp53. We found that, in this context, Atrx deficiency induced widespread alterations in chromatin accessibility and organization, which in turn led to dramatic shifts in gene expression. Among the altered transcriptional networks were pathways implicated in cellular motility and invasion, an established feature of diffusely infiltrating gliomas. Intriguingly, Atrx-deficient NPCs also exhibited significantly increased transwell migration. Our findings demonstrate that ATRX deficiency promotes disease-relevant biological behavior by modulating chromatin accessibility and influencing gene expression. We are now performing detailed epigenetic and biochemical studies to identify the precise transcriptional events mediating these effects. We are also investigating how IDH mutations influence the genomic distribution of ATRX, thereby modulating its function and the consequences of its deficiency. Citation Format: Jason T. Huse. Investigating the functional consequences of ATRX deficiency in glioma. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr IA12.
Effects of electronic chemotherapy scheduling and communication tools on chemotherapy delivery.
Authors: S. Singh, M. E. Trudeau, B. De Mendonca, M. C. Cheung
Journal: Journal of Clinical Oncology (2011)

e16504 Background: The Odette Cancer Centre (OCC) manages over 21,000 chemotherapy patient visits per year. Barriers to efficient delivery of chemotherapy include scheduling inefficiencies and staff communication. These issues were addressed via two mechanisms: (1) chemotherapy scheduling tool (2) electronic communication tool for nurses and pharmacy staff. Methods: An electronic Chemotherapy Appointment Reservation Manager (CHARM) was developed. CHARM was configured to calculate treatment times based on preparation and administration times. A web based communication tool was developed to facilitate communication. Data was prospectively collected for 2-week intervals in 2009 and 2010 to assess the effect of both programs. A flow-time analysis and staff satisfaction surveys were conducted comparing the time frames. Results: For 2009, data was collected for 381/796 total patients treated in the two-week period (47.9 %). For 2010, data was collected for 602/836 total patients treated (5% volume increase). In 2010, a reduction in phone calls (for chemotherapy approval) between the nurses and pharmacy of 89% was observed. Order clarifications were reduced by 91%. Thirty-six percent of patients started treatment +/- 30 min of scheduled time in both time frames. However, patients treated >30 mins after their scheduled time increased (20.7% to 71.1%). Nurses were more likely to agree that communication positively impacted on chemotherapy administration after implementation of the communication tool (80% vs. 37%). Staff concern regarding wait times and patient flow remained high (100% in 2010 vs. 90% in 2009). Conclusions: Introduction of a communication tool has resulted in positive outcomes in treatment delivery at OCC. Despite the implementation of CHARM, there was little change in patient flow. Possible explanations include increased patient volumes without infrastructure increases and missing chemotherapy orders. Further improvement may require process changes such as correct bed assignments and closer adherence to CHARM scheduling. Time from patient registration to: 2009 (mins) 2010 (mins) Patient on chemotherapy unit 33 43 Nursing approval 79 85 Pharmacy approval 89 94 Initiation of treatment 126 150
Posttraumatic stress disorder as an insanity defense: medicolegal quicksand
Authors: L F Sparr, R M Atkinson
Journal: American Journal of Psychiatry (1986)

A growing awareness of posttraumatic stress disorder has led to recent use of the disorder as a legal defense against criminal responsibility for both violent and nonviolent crimes. Diagnosis of posttraumatic stress disorder is difficult because the symptoms are mostly subjective, often nonspecific, usually well publicized, and, therefore, relatively easy to imitate. Accurate psychiatric testimony in such cases requires diligent searching for collateral sources of information. The authors argue that the insanity defense is appropriate only in the rare instance that a dissociative episode related to posttraumatic stress disorder directly leads to criminal activity.
Abstract B32: Serum calcium and serum albumin can discriminate malignant from benign pelvic masses.
Authors: Gary G. Schwartz, Michael G. Kelly, Stuart S. Winkler, Samuel S. Lentz, Steve H. Berliner, Melissa F. Swain, Halcyon G. Skinner
Journal: Clinical Cancer Research (2016)

Abstract Background: Biomarkers that aid in the differential diagnosis of malignant pelvic masses from benign ones prior to surgery are needed in order to triage women with malignant masses to appropriate specialist care. Because high albumin-adjusted serum calcium predicted ovarian cancer among women without evidence of disease, we hypothesized that it might predict cancer among women with pelvic masses that were evident radiographically. Methods: We studied a cohort of 514 women with pelvic masses who underwent resection at Wake Forest University Baptist Medical Center from July 2009 through June 2013. We divided patients into a “training” set, to identify associations in the data, and a “testing” set, to confirm them. Data were obtained from medical records. A best fit model was selected using the Akaike Information Criterion. Results: Albumin-adjusted serum calcium was significantly higher in women with malignant vs. benign masses (P= 0.0004). High normocalcemia, i.e., an albumin-adjusted serum calcium ≥ 10 mg/dL, occurred in 53% of women with malignant tumors vs. 12% of benign tumors. High normocalcemia was associated with a ~14-fold increased risk of malignancy. The best fit model (Overall) included albumin, calcium, and non-linear terms. Overall achieved an AUC of 0.83 with a sensitivity of 72% and specificity of 83%, a PPV of 71% and a NPV of 85%. Conclusions: A model using serum calcium and serum albumin to predict malignancy in women with pelvic masses has high sensitivity and is economical. Impact: Our model can help triage women with ovarian cancer to appropriate surgical care. Citation Format: Gary G. Schwartz, Michael G. Kelly, Stuart S. Winkler, Samuel S. Lentz, Steve H. Berliner, Melissa F. Swain, Halcyon G. Skinner. Serum calcium and serum albumin can discriminate malignant from benign pelvic masses. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B32.
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
Authors: A.M. Udager, T.-Y. Liu, S.L. Skala, M.J. Magers, A.S. McDaniel, D.E. Spratt, F.Y. Feng, J. Siddiqui, X. Cao, K.L. Fields, T.M. Morgan, G.S. Palapattu, A.Z. Weizer, A.M. Chinnaiyan, A. Alva, J.S. Montgomery, S.A. Tomlins, H. Jiang, R. Mehra
Journal: Annals of Oncology (2016)
Are All Recently Detoxified Alcoholics Depressed?
Authors: Martin H. Keeler, Inga Taylor, William C. Miller
Journal: American Journal of Psychiatry (1979)

Reports of the prevalence of depression among alcoholics vary from 3% to 98%; the authors attribute this variation to the use of different diagnostic criteria. They used clinical diagnosis, the Hamilton Depression Rating Scale, the Zung Self-Rating Depression Scale, and the MMPI to diagnose 35 men recently withdrawn from alcohol. The percentages of depression diagnosed were 8.6%, 28%, 66%, and 43%, respectively. The authors point out that the Hamilton, Zung, and MMPI scales are not diagnostic of depression in themselves and that accurate diagnosis of depression in alcoholics will reduce inappropriate treatment of nondepressed alcoholics and ensure careful treatment of the truly depressed.
Minor physical anomalies in alcoholic and schizophrenic adults and hyperactive and autistic children
Authors: C T Gualtieri, A Adams, C D Shen, D Loiselle
Journal: American Journal of Psychiatry (1982)

Minor physical anomalies occur with increased frequency in retarded, hyperactive, and autistic children, which suggests the effects of genetic influences or a toxic early uterine environment. The author's findings concur with previously published reports concerning hyperactive and autistic children. Extending these studies to adult patients, they found an increased incidence of minor physical anomalies in schizophrenic adults. Alcoholic adults did not have a greater number of anomalies than normal adults, but the distribution among alcoholics appeared to be bimodal, suggesting heterogeneity within this group.
Epigenetic Changes in Diabetes and Cardiovascular Risk
Authors: Samuel T. Keating, Jorge Plutzky, Assam El-Osta
Journal: Circulation Research (2016)

Cardiovascular complications remain the leading causes of morbidity and premature mortality in patients with diabetes mellitus. Studies in humans and preclinical models demonstrate lasting gene expression changes in the vasculopathies initiated by previous exposure to high glucose concentrations and the associated overproduction of reactive oxygen species. The molecular signatures of chromatin architectures that sensitize the genome to these and other cardiometabolic risk factors of the diabetic milieu are increasingly implicated in the biological memory underlying cardiovascular complications and now widely considered as promising therapeutic targets. Atherosclerosis is a complex heterocellular disease where the contributing cell types possess distinct epigenomes shaping diverse gene expression. Although the extent that pathological chromatin changes can be manipulated in human cardiovascular disease remains to be established, the clinical applicability of epigenetic interventions will be greatly advanced by a deeper understanding of the cell type-specific roles played by writers, erasers, and readers of chromatin modifications in the diabetic vasculature. This review details a current perspective of epigenetic mechanisms of macrovascular disease in diabetes mellitus and highlights recent key descriptions of chromatinized changes associated with persistent gene expression in endothelial, smooth muscle, and circulating immune cells relevant to atherosclerosis. Furthermore, we discuss the challenges associated with pharmacological targeting of epigenetic networks to correct abnormal or deregulated gene expression as a strategy to alleviate the clinical burden of diabetic cardiovascular disease.
Measles Antibodies in Multiple Sclerosis
Authors: W A SIBLEY, J M FOLEY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract IA01: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures
Authors: James P. Allison
Journal: Cancer Research (2016)

Abstract The existence of multiple non-redundant inhibitory pathways that limit T cell responses offers novel strategies for mobilizing the immune system to attack cancer cells. The best characterized of these immune checkpoints is CTLA-4, which inhibits T cell proliferation by interfering with the interaction of the costimulatory molecule CD28 with its ligands B7-1 and B7-2 on the surface of antigen presenting cells. Antibodies to CTLA-4 have proven effective against multiple tumor types in both pre-clinical and clinical studies. Ipilimumab, an antibody to human CTLA-4, showed long term (&amp;gt;4 years) survival benefit in about 20% of patients in a randomized, placebo-controlled trial in late stage melanoma. In 2011 it was approved by the FDA for treatment of late stage melanoma and is now a standard of care for that disease. The mechanism(s) of action of anti-CTLA-4 are still being elucidated. We and others have shown that CLTA-4 limits T cell proliferation by a cell intrinsic mechanism. However, there is also evidence that anti-CTLA-4 has to engage the target on both effector (Teff) and regulatory (Treg) T cells. Thus anti-CTLA-4 exerts its anti-tumor effects by multiple mechanisms. PD-1, another checkpoint, recruits a phosphatase and seems to interfere with T cell antigen receptor mediated signaling. It has two ligands, PD-L1 and PD-L2, which are both expressed on dendritic cells. However, many tumor cells also express PD-L1. Antibodies to PD-1 and PD-L1 have both shown objective responses against several tumor types in clinical trials with response rates of about 25%. A recent phase II trial of a combination of anti-PD-1 and anti-CTLA-4 in melanoma showed objective responses in about 50% of late stage melanoma patients. Emerging data suggest that T cell responses are largely directed toward neoantigens arising as a result of mutational events associated with the carcinogenesis. While all tumors with antigens recognizable by the immune system should be targets for checkpoint blockade, it is becoming clear that certain types of tumors with lower burdens of mutations (eg. prostate, breast, and kidney cancer) present special challenges for immune therapy. Strategies for effective treatment of such tumors will be discussed. Citation Format: James P. Allison. Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA01.
Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report
Authors: Wilhelm Woessmann, Martin Zimmermann, Birgit Burkhardt, Andrea Meinhardt, Christine Rosenbusch, Vera Vaillant, Ilske Oschlies, Wolfram Klapper, Felix Niggli, Andishe Attarbaschi, Georg Mann, Martin Schrappe, Alfred Reiter
Journal: Blood (2014)
The impact of BMI on early colorectal neoplastic lesions and the role of endoscopic diagnosis:. An Italian observational study
Authors: Marco Cannistrà, Michele Ruggiero, Raffaele Grande, Emanuele Sireno, Rosario Colace, Riccardo Domenico Ferdinando Calabria, Alberico Guido, Antonia Rizzuto, Rosario Sacco, Raffaele Serra, Giuseppe Sammarco
Journal: International Journal of Surgery (2016)
Haiti
Authors: David Muller
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase 1–2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma
Authors: M. Duvic, S. Ziari, E. A. Olsen, F. M. Foss
Journal: Journal of Clinical Oncology (2004)

6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells. Bcx-1777 is a small molecular weight inhibitor of purine nucleoside phosphorylase (PNP). PNP deficiency results in an accumulation and preferential phosphorylation of deoxyguanosine (dGuo) leading to T cell apoptosis and decreased response to mitogens. Thus, PNP inhibition may be expected to be therapeutic. Methods: A multi-center, open-label dose escalation phase 1–2 study was conducted in patients with refractory CTCL who had failed four prior therapies (stage IB-IIA) or one systemic therapy (stage IIB-IVB). Bcx-1777 was administered by 30 min IV infusion q. 12 hrs.x 9 doses and courses were repeated every 16 days x 3. Pharmacokinetic sampling was performed. Clinical response was determined each course using a weighted composite of disease assessment from baseline. Safety visits were conducted weekly. Results: Ten CTCL patients have received at least one course of therapy at dose levels of 40 mg/m2 (n=4), 60 or 90 mg/m2 (n=3 each). One CR occurred at the first dose level, but the patient developed lethal catheter related sepsis. Minor responses were seen in four SS pts. who experienced improved erythroderma, pruritus, adnenopathy, and decreased numbers of atypical cells by flow cytometry. Side effects were minimal and included headache following the infusion (5 pts), pedal edema (4 pts), and vertigo, myalgia, or herpes zoster (1 pt, each). Hyperuricemia was seen in a SS pt. but no other dose limiting toxicities were experienced. Plasma deoxyguanosine (dGuo) levels were increased during therapy. Conclusions: This preliminary dose escalation study supports further investigation and formulation of the PNP inhibitor Bcx 1777 for treatment of CTCL patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biocryst
Current trends in the training of family therapists
Authors: E W Beal
Journal: American Journal of Psychiatry (1976)

The author describes and compares training programs for family therapists at 15 centers in 9 major U.S. cities, using a scale that reflects the spectrum of theoretical approaches to family therapy. At one end of the spectrum are the centers with an experiential orientation, at the other end are those with a structural orientation, and in the middle are those which combine these orientations. He concludes that although creative theoretical advances are being made at a few of these centers, the quality and design of training at the remaining centers suffer from the absence of an adequate diagnostic nomenclature for family therapy and from an insufficiently designed conceptual framework.
INTERFERON REGULATORY FACTOR-1 IS RESPONSIBLE FOR CARDIAC PROTECTIVE EFFECT OF 5-AZACYTIDINE ON MACROPHAGES IN MYOCARDIAL INFARCTION
Authors: Young Keun Ahn, Jeong Hye-Yun, Kim Yong Sook, Kang Hye Jin, Kang Wan Seok
Journal: Journal of the American College of Cardiology (2014)
Breast Cancer and Hormonal Therapy in Postmenopausal Women
Authors: Agnès Fournier, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon
Journal: New England Journal of Medicine (2009)

et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Glass Cloth as a Substrate for Tissue Culture&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Douglas Warner, Ph.D., Charlotte Hanawalt, B. A., Fritz Bischoff, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1949)

Glass Cloth as a Substrate for Tissue Culture Get access Douglas Warner, Ph.D., Douglas Warner, Ph.D. Tissue Culture and Chemical Laboratories, Santa Barbara Cottage Hospital Research Institute, Santa Barbara, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Charlotte Hanawalt, B. A., Charlotte Hanawalt, B. A. Tissue Culture and Chemical Laboratories, Santa Barbara Cottage Hospital Research Institute, Santa Barbara, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Fritz Bischoff, Ph.D. Fritz Bischoff, Ph.D. Tissue Culture and Chemical Laboratories, Santa Barbara Cottage Hospital Research Institute, Santa Barbara, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 1, August 1949, Pages 67–74, https://doi.org/10.1093/jnci/10.1.67 Published: 01 August 1949 Article history Received: 20 December 1948 Published: 01 August 1949